The cancer menace affects a lot of people across the world. The disease has caused pain and affliction to lot families across the globe. In America alone, at least 40 percent of adults are diagnosed with cancer at some point in their lives. National Cancer Institute revealed that close to 15 million people in the U.S. were diagnosed with cancer in 2014. The figures are expected to shoot to close to 20 million in the coming ten years. These figures can, however, come down if there is adequate information on specific treatment options for cancer in our hospitals. Lack of adequate information is one of the hindrances to the treatment of cancer.
Cancer Centers of America are one of the organizations that have put a spirited fight against cancer. The organization, through their affiliate hospitals, has teamed up with Nanthealth and Allscripts to roll out a new program that will enable quick access to critical information needed during the cancer treatment process.The new platform created by the three organizations will allow clinicians and researchers to access a pool of cancer care data. The database will continuously be updated by oncologists and physicians who have experience and expertise in dealing with different types of cancer. The critical information in the database can be accessed within a few clicks.
The three organizations launched the partnership in 2016 as they tried to brainstorm on how they can deliver better services to the cancer patients. The new platform is known as clinical pathways, and it will allow the eviti system by Nanthealth to access the Allscripts Sunrise EHR.The Allscripts Sunrise EHR contains more than 2700 evidence-based treatments which allow clinicians and oncologists to weigh on different treatment possibilities that they can recommend to their patients. The integrity of the clinical pathways program is assured since it is maintained by highly experienced oncologists and researchers in America.Through the clinical pathways platform, oncologists can create customized treatment plans with the input from the patients. The platform also helps them to compare treatment options and costs, and also examine other complimentary services that a cancer patient would consider.
In 1997 Clay Siegall co-founded Seattle Genetics Company on a foundation of drug development, scientific innovation, and rigorous research in addition to the passion of serving patients. Mr. Clay is the chairman of the Board, the CEO and the company’s president. Seattle Genetic Company develops a diverse group of preclinical and clinical product candidates with the aim of cancer varieties and autoimmune indications. Through Siegall’s leadership, he has guided the company to its recent position of Antibody Drug Conjugate (ADC) development as well as securing the FDA (2011) approval of its first ADC products.
Under collaboration with Genentech, MedImmune, CuraGen and Takeda Pharmaceutical companies, ADCETRIS is currently a global product approved in more than 60 countries. Noteworthy to mention, Dr. Clay has guided Seattle Genetic Company to capital-raising activities attaining $1.2 billion from private and public funding. Moreover, the company has gone through premeditated licenses such as AbbVie and Pfizer for the ADC technologies which have resulted to more than $325 million. Clay Siegel is an excellent example of hardworking man from his overall achievements since there are few genetic companies worldwide that can be contrasted with his work.
In social media perspective, the gentleman has created immersive awareness about cancer and the research in place. To begin with, his Facebook page well known of valuable information of conferences discussions, resolution, and new ideas. Furthermore, Clay Siegall website is available in the essence of the company and development of the research. Additionally, he considers rapid technology development hence medicine elements should develop with it.
In conclusion, since 1997 Dr. Clay has done extremely recommendable work from Seattle Genetic company launch to its current position. Moreover, a lot of people are in hope for better things to in future from the rise of medicine technology. Finally, the genetic industry is currently competitive than ever though a lot of people are looking up to work with Clay Siegall in this industry as from his experience.
Seattle Genetics is an innovative biotechnological company that is focused on discovering new cancer treatments. CEO Clay Siegall built the company to assist his patients through drug developments, medical research, and new scientific discoveries. Seattle Genetics has generated more than $300 million under Dr. Siegall’s leadership by entering multiple licenses with big pharmaceutical companies such as Pfizer, GlaxoSmithKline, Roche, and Abbvie. He has raised more than $675 million in revenues for his biotechnological company through public and private offerings to continue working on antibody-drug conjugates (ADCs)to cure cancer.
Through reliable scientific inquiry, integrity, and revolutional therapies, Seattle Genetics has built a strong and honest corporate culture. Clay Seagall has structured his company to collaborate on new CDCs through teamwork. Dr. Siegall also organized a positive work environment where new contributions from staff members are encouraged. Mutual respect at the company has led to Seattle Genetics employees focusing on ways to improve health together through a shared dedication.
ADCs are important to Seattle Genetics because they can spare healthy cells which greatly reduces the harmful effects of typical chemotherapy treatments. As a result, anti-tumor antibodies can directly attack cancer cells while sparing healthy cells. The biotechnological company does not just offer one type of drug to treat cancer, but a whole family of treatments meant to target different types of cancer cells. There are 20 different types of ADCs being researched that show promise for helping cancer patients live and feel better. ADCETRIS is one type of ADC that is being evaluated as a potential treatment for lymphomas. SGN-CD322 is also being evaluated as a possible treatment for the advanced stages of Leukemia.
Seattle Genetics is a leader in cancer treatment research. The innovative approach led by Clay Seagall has helped the company earn a reputation for being both innovative and compassionate.
Seattle Genetics is one of the largest cancer research centers in the world. For over two decades now, the company has made remarkable achievements in cancer research. The company is behind several anti-body therapies used in treatment of cancer. It is a leader in Antibody Drug Conjugates (ADC) production and continues to work on various innovations and development of therapeutic agents that are used to fight cancer cells.
One of the individuals behind Seattle Genetics’ success is Clay Siegall, the founder, CEO and chairman of the company’s board. Driven by passion and boldness, Siegall took advantage of Bristol Mayer’s decision to shut down its operations in Seattle to start his own company. He found the company with the aim to bring hope to cancer patients by helping them fight the disease using ADC therapy.
Despite financial challenges that presented at the initial stages, Clay Siegall did not give up. He managed to convince several venture capitalists, who funded the company with a whopping $ 7 million. Nine months later, he managed to get an additional $30 million by VC funding. Clay Siegall decided to make the company public in 2001 and raised about $51 million. Under his leadership, the company has raised more than $300 million so far.
Clay Siegall attended Maryland University and graduated with a bachelor of science in Zoology. He also went to George Washington University and graduated with a Doctor of Philosophy in Genetics. His exemplary work has never gone unnoticed. In 2013, he proudly received Alumnus of the Year for Computer and Natural Sciences award from the University of Maryland. He also bagged Entrepreneur of the Year award in 2012. He has been a director in Ultragenyx Pharmaceutical, Mirna Therapeutics, Alder Biopharmaceuticals.
Clay Siegall continues to hold strongly the values and vision of Seattle Genetics. He believes that cancer eradication is possible. Together with his organization, Siegall is already improving the lives of people through antibody therapies empowered by innovativeness. The company works with a team of brilliant individuals who rely on a strong culture built around the values of integrity, honesty, teamwork and scientific excellence.
The board of directions at Mirna Therapeutics has added Clay Siegall to their ranks because of his knowledge of the medical industry. Clay Siegall started Seattle Genetics so that he would be able to make it easy for people to get the therapy that they need. It is something that has helped people to make sure that they can recover from the things that ill them, and now he is going to help Mirna make sure that they can offer their customers and patients will be able to recover from cancer.
Clay Siegall brings his own take on how to help people to the board, and he is trying to make sure that people will be able to get the help they need making better medications. Clay Siegall knows that he will be able to help people get better even at the companies that he does not work for, but that is because he wants to know that he will be able to help all people. He wants to think of the medical industry as one big family that can all work together.
It is very easy for people to recover from cancer when they are receiving help from companies like Mirna and Seattle Genetics. Seattle Genetics is an antibody based company that works on these therapies every day, and it was started by Clay Siegall to be sure that he could sell his medications to the public. He has two drugs in testing for his company, and he is also going to be sure that people are going to see more and more of the medications that will cure them.
His time at Mirna will be helpful for the company. Clay Siegall can bring his perspective to people who are trying to get better, and he wants to be sure that he can improve the care for all the patients his company reaches.